Stacey Ricci, MEng, ScD

Director (Acting), Scientific Review Staff
Office of Therapeutic Biologics and Biosimilars
FDA

Dr. Ricci has worked in CDER/FDA for over 11 years and is currently the Director of Scientific Review in the Office of Therapeutic Biologics and Biosimilars (OTBB). OTBB works collaboratively with CDER Offices and Review divisions responsible for providing scientific and regulatory advice to sponsors seeking to develop biosimilar and interchangeable products. OTBB also contributes to the development of policies, procedures and guidance necessary to further implement the Biologics Price Innovation and Competition Act.